Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Dose-escalation, Bi-weekly Phase I+II Clinical Trial in Treating Patients With Limited Stage of High-grade Osteosarcoma of Maintenance Therapy After Adjuvant Chemotherapy

Next Previous
Trial Profile

An Open-label, Dose-escalation, Bi-weekly Phase I+II Clinical Trial in Treating Patients With Limited Stage of High-grade Osteosarcoma of Maintenance Therapy After Adjuvant Chemotherapy

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Socazolimab (Primary)
  • Indications Osteosarcoma
  • Focus Adverse reactions
  • Sponsors Zhaoke Pharmaceutical (Hefei)

    • Most Recent Events

    • 05 Dec 2022 Results (n=21; Between October 2018 and October 2019) assessing the safety and preliminary efficacy of ZKAB001 as maintenance therapy for localized high-grade osteosarcoma patients to reduce the risk of recurrence and metastasis, published in the Clinical Cancer Research.
    • 17 Sep 2018 Status changed to recruiting.
    • 22 Mar 2018 According to Lee's Pharmaceutical Holdings Limited website, the Company has received approval to proceed with the clinical trials for ZKAB001. Clinical data from this trial is expected to be available by the end of 2019, and positive results could lead to conditional approval of the antibody prior to a confirmatory Phase III study. Link: http://www.leespharm.com/file/investor/LTN20180322470.pdf
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top